Pay in 4 interest-free payments of $5.17 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Hormonal shifts can make your scalp either oilier or drier than usual
L-carnitine ameliorates oxidative damage due to chronic renal failure in rats
In PMOS, they may be used when the clinical picture fits, especially when higher weight or metabolic risk is part of the case
As the oxidative burden on the mitochondria is lifted, these organelles can begin to shift away from inefficient anaerobic glycolysis (which produces the brain-fog-inducing lactate) and back toward efficient aerobic ATP production
Primary candidates for GLP-1 therapy include: Patients with type 2 diabetes and inadequate glycemic control despite metformin therapy Individuals with type 2 diabetes and established atherosclerotic cardiovascular disease Patients with type 2 diabetes and multiple cardiovascular risk factors (hypertension, dyslipidemia, obesity) Adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with weight-related comorbidities Patients with metabolic syndrome who have not achieved adequate risk factor control with lifestyle modification For patients with dyslipidemia, GLP-1 agents may be particularly valuable when combined with statin therapy in those who have not reached LDL-C goals or who have persistent hypertriglyceridemia despite statin treatment
Endocrinology, 150(12), 54785487
US$ 26.10
:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)
US$ 25.55
US$ 20.27
US$ 22.41
